Evidence map›Paper›PMID 40623958›Full record

SynthesisBJU international2025

Natural history of treated and untreated renal oncocytoma: a systematic review and meta-analysis.

Francesco Edwards, Jack B Fanshawe, Joana Neves, Michael Aitchison, Soha El-Sheikh, Archie Hughes-Hallett, Ahmed Marous, Faiz Mumtaz, John Withington, Prasad Patki and 7 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Francesco EdwardsFaculty of Life Sciences and Medicine, King's College London, London, UK.
Jack B FanshaweGuy's and St Thomas' NHS Foundation Trust, London, UK.
Joana NevesDivision of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-8578-9893
Michael AitchisonDivision of Surgery and Interventional Sciences, University College London, London, UK.
Soha El-SheikhDepartment of Pathology, Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.
Archie Hughes-HallettDepartment of Urology, Imperial College NHS Healthcare Trust, London, UK.
Ahmed MarousBristol Urological Institute, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Faiz MumtazDivision of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-0211-3936
John WithingtonDivision of Surgery and Interventional Sciences, University College London, London, UK.
Prasad PatkiDepartment of Urology, Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.
Ravi BarodDivision of Surgery and Interventional Sciences, University College London, London, UK.
Pedro SilvaDepartment of Urology, Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.
Rebecca VarleyManchester Centre for Transplantation, Manchester Royal Infirmary, Manchester, UK.ORCID 0000-0001-9356-0266
Wilson ToDepartment of Urology, University College Hospital London, London, UK.
Axel BexDivision of Surgery and Interventional Sciences, University College London, London, UK.
Hannah WarrenDivision of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-4106-2705
Maxine G B TranDivision of Surgery and Interventional Sciences, University College London, London, UK.ORCID 0000-0002-6034-4433

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history of treated and untreated renal oncocytoma to inform clinical guidelines and shared decision-making.

methodsA systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). We systematically reviewed MEDLINE, EMBASE, CENTRAL and Clinicaltrials.gov from inception to 18 August 2023. Studies that reported outcomes during follow-up for adult patients with treated and untreated histologically confirmed renal oncocytoma were included. The Joanna Briggs Institute tool was used to assess risk of bias for included studies. We present a narrative review and meta-analysis.

resultsThere are no reports of distant metastases or disease-related death for oncocytoma on active surveillance. Most oncocytomas on surveillance show limited growth (<2 mm/year) and minimal renal function decline (-1 mL/min/1.73m

conclusionActive surveillance of oncocytoma is oncologically safe and allows patients to avoid the risk of morbidity and mortality with treatment. Imaging surveillance after active treatment can be safely omitted. The literature would benefit from prospective cohort studies of oncocytomas on surveillance, reporting surveillance protocols, and clinical outcomes including reasons for transition to active treatment.

Indexed as

Adenoma, OxyphilicKidney NeoplasmsWatchful WaitingHumansablationkidneyoncocyticoncocytomaprognosisrenalsurgerysurveillance

Identifiers

PMID40623958
PMCPMC12415324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.